Drugs / CryJ2-DNA-LAMP plasmid vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02146781 | Jun 2014 → Mar 2015 | allergic rhinitis | Immunomic Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01966224 | Sep → Dec 2013 | allergic disease | Immunomic Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01707069 | Oct 2012 → May 2013 | allergic disease | Immunomic Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CryJ2-DNA-LAMP plasmid vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01707069 ↗ |
| Known as | CryJ2-DNA-LAMP vaccine | “Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative.” NCT01707069 ↗2“Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative.” NCT02146781 ↗ “CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative.” NCT01966224 ↗ |
| Modality | Vaccine | “The vaccine is called CryJ2-DNA-LAMP Plasmid vaccine.” NCT01966224 ↗ |
| Route | Intramuscular | “Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection.” NCT01707069 ↗ |